A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Luckily for you, StockStory helps you navigate which companies are truly worth holding. That said, here is one low-volatility stock providing safe-and-steady growth and two stuck in limbo.
Two Stocks to Sell:
Jazz Pharmaceuticals (JAZZ)
Rolling One-Year Beta: 0.66
Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.
Why Do We Think Twice About JAZZ?
- Sales trends were unexciting over the last two years as its 4.7% annual growth was below the typical healthcare company
- Issuance of new shares over the last five years caused its earnings per share to fall by 8.7% annually while its revenue grew
- 5× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
Jazz Pharmaceuticals is trading at $166.31 per share, or 7.7x forward P/E. Dive into our free research report to see why there are better opportunities than JAZZ.
Franklin BSP Realty Trust (FBRT)
Rolling One-Year Beta: 0.34
Operating as a specialized real estate investment trust (REIT) with roots dating back to 2012, Franklin BSP Realty Trust (NYSE: FBRT) originates and manages a diversified portfolio of commercial real estate debt investments secured by properties in the United States and abroad.
Why Do We Pass on FBRT?
- Annual net interest income growth of 6.1% over the last five years was below our standards for the banking sector
- Earnings per share have contracted by 51.5% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance
- Products and services are facing significant credit quality challenges during this cycle as tangible book value per share has declined by 7.5% annually over the last five years
At $9.01 per share, Franklin BSP Realty Trust trades at 0.6x forward P/B. Read our free research report to see why you should think twice about including FBRT in your portfolio.
One Stock to Watch:
Elevance Health (ELV)
Rolling One-Year Beta: 0.25
Formerly known as Anthem until its 2022 rebranding, Elevance Health (NYSE: ELV) is one of America's largest health insurers, serving approximately 47 million medical members through its network-based managed care plans.
Why Are We Fans of ELV?
- Annual revenue growth of 10.3% over the last five years was above the sector average and underscores its products and services value to customers
- Dominant market position is represented by its $197.6 billion in revenue, which gives it negotiating power over membership pricing and reimbursement rates
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures
Elevance Health’s stock price of $337.50 implies a valuation ratio of 12.9x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
